Guizhounli Pharmaceutical Co (SHSE:603439) LT-Debt-to-Total-Asset : 0.08 (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Guizhounli Pharmaceutical Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.08.

Guizhounli Pharmaceutical Co's long-term debt to total assets ratio increased from Sep. 2023 (0.00) to Sep. 2024 (0.08). It may suggest that Guizhounli Pharmaceutical Co is progressively becoming more dependent on debt to grow their business.

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Guizhounli Pharmaceutical Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Chart

Guizhounli Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

Guizhounli Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	0.09	0.09	0.08	0.08

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Calculation

Guizhounli Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	254.318	/	2920.451
	=	0.09

Guizhounli Pharmaceutical Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	232.047	/	3058.607
	=	0.08

Guizhounli Pharmaceutical Co (SHSE:603439) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Guizhounli Pharmaceutical Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Guizhounli Pharmaceutical Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Guizhounli Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Guizhou Sanli Pharmaceutical Co Ltd (SHSE:603439) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Xiayun Industrial Park, Pingba District, Guizhou Province, Anshun, CHN, 561000

Website

http://www.gz-sanli.com

Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.

Executives

Zhang Hai	Director
Wang Jue Ben	senior management
Zhang Hong Yu	Directors, senior managers
Wang Yi	senior management
Zhang Qian Fan	Directors, senior managers
Sheng Yong Jian	Director

Guizhounli Pharmaceutical Co Headlines

No Headlines